作者
Stefan Worgall, Dolan Sondhi, Neil R Hackett, Barry Kosofsky, Minal V Kekatpure, Nurunisa Neyzi, Jonathan P Dyke, Douglas Ballon, Linda Heier, Bruce M Greenwald, Paul Christos, Madhu Mazumdar, Mark M Souweidane, Michael G Kaplitt, Ronald G Crystal
发表日期
2008/5/1
期刊
Human gene therapy
卷号
19
期号
5
页码范围
463-474
出版商
Mary Ann Liebert, Inc.
简介
Late infantile neuronal ceroid lipofuscinosis (LINCL) is an autosomal recessive, neurodegenerative lysosomal storage disease affecting the CNS and is fatal by age 8 to 12 years. A total average dose of 2.5 × 1012 particle units of an adeno-associated virus (AAV) serotype 2 vector expressing the human CLN2 cDNA (AAV2CU hCLN2) was administered to 12 locations in the CNS of 10 children with LINCL. In addition to safety parameters, a neurological rating scale (primary variable) and three quantitative magnetic resonance imaging (MRI) parameters (secondary variables) were used to compare the rate of neurological decline for 18 months in treated subjects compared with untreated subjects. Although there were no unexpected serious adverse events that were unequivocally attributable to the AAV2CU hCLN2 vector, there were serious adverse effects, the etiology of which could not be determined under the …
引用总数
20082009201020112012201320142015201620172018201920202021202220232024327324635353339363326271821221710